These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
824 related articles for article (PubMed ID: 30375207)
1. Patient-reported outcomes in hidradenitis suppurativa. Vellaichamy G; Braunberger TL; Jones JL; Peacock A; Nahhas AF; Hamzavi IH G Ital Dermatol Venereol; 2019 Apr; 154(2):137-147. PubMed ID: 30375207 [TBL] [Abstract][Full Text] [Related]
2. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773 [TBL] [Abstract][Full Text] [Related]
3. Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research. Otten M; Augustin M; Blome C; Topp J; Niklaus M; Hilbring C; Bechara FG; Pinter A; Zouboulis CC; Anzengruber F; Kirsten N Acta Derm Venereol; 2023 Jan; 103():adv00859. PubMed ID: 36129249 [TBL] [Abstract][Full Text] [Related]
4. Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Thorlacius L; Garg A; Riis PT; Nielsen SM; Bettoli V; Ingram JR; Del Marmol V; Matusiak L; Pascual JC; Revuz J; Sartorius K; Tzellos T; van der Zee HH; Zouboulis CC; Saunte DM; Gottlieb AB; Christensen R; Jemec GBE Br J Dermatol; 2019 Sep; 181(3):483-491. PubMed ID: 30724351 [TBL] [Abstract][Full Text] [Related]
5. The psychosocial impact of hidradenitis suppurativa. Gooderham M; Papp K J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S19-22. PubMed ID: 26470609 [TBL] [Abstract][Full Text] [Related]
6. Achieving Hidradenitis Suppurativa Response Score is Associated with Significant Improvement in Clinical and Patient-reported Outcomes: Post Hoc Analysis of Pooled Data From PIONEER I and II. Kimball AB; Tzellos T; Calimlim BM; Teixeira HD; Geng Z; Okun MM Acta Derm Venereol; 2018 Nov; 98(10):932-937. PubMed ID: 30085324 [TBL] [Abstract][Full Text] [Related]
8. Hidradenitis Suppurativa: A Guide for the Practicing Physician. Woodruff CM; Charlie AM; Leslie KS Mayo Clin Proc; 2015 Dec; 90(12):1679-93. PubMed ID: 26653298 [TBL] [Abstract][Full Text] [Related]
9. Assessing the psychological burden of patients with hidradenitis suppurativa. Frings VG; Bauer B; Glöditzsch M; Goebeler M; Presser D Eur J Dermatol; 2019 Jun; 29(3):294-301. PubMed ID: 31145081 [TBL] [Abstract][Full Text] [Related]
10. New treatments and new assessment instruments for Hidradenitis suppurativa. van Straalen KR; Ingram JR; Augustin M; Zouboulis CC Exp Dermatol; 2022 Sep; 31 Suppl 1(Suppl 1):33-39. PubMed ID: 35582833 [TBL] [Abstract][Full Text] [Related]
11. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Kimball AB; Jemec GB; Yang M; Kageleiry A; Signorovitch JE; Okun MM; Gu Y; Wang K; Mulani P; Sundaram M Br J Dermatol; 2014 Dec; 171(6):1434-42. PubMed ID: 25040429 [TBL] [Abstract][Full Text] [Related]
12. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295 [TBL] [Abstract][Full Text] [Related]
13. Hidradenitis suppurativa and associated diseases. Pescitelli L; Ricceri F; Prignano F G Ital Dermatol Venereol; 2018 Jun; 153(3 Suppl 2):8-17. PubMed ID: 30468375 [TBL] [Abstract][Full Text] [Related]
14. Ertapenem - a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa. Braunberger TL; Nartker NT; Nicholson CL; Nahhas AF; Parks-Miller A; Hanna Z; Jayaprakash R; Ramesh MS; Rambhatla PV; Hamzavi IH Int J Dermatol; 2018 Sep; 57(9):1088-1093. PubMed ID: 29774531 [TBL] [Abstract][Full Text] [Related]
15. Major gaps in understanding and treatment of hidradenitis suppurativa. Hoffman LK; Ghias MH; Garg A; Hamzavi IH; Alavi A; Lowes MA Semin Cutan Med Surg; 2017 Jun; 36(2):86-92. PubMed ID: 28538750 [TBL] [Abstract][Full Text] [Related]
16. Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe. Willems D; Hinzpeter EL; Van der Zee HH; Sayed CJ; Ingram JR; Beaudart C; Evers SMAA; Hiligsmann M Patient; 2023 Mar; 16(2):153-164. PubMed ID: 36630078 [TBL] [Abstract][Full Text] [Related]
17. Electronic Patient-Reported Outcomes in Hidradenitis Suppurativa: Content Validity and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary, Hidradenitis Suppurativa Symptom Questionnaire, and Hidradenitis Suppurativa Quality of Life Questionnaire. Ingram JR; Ciaravino V; Rolleri R; Pansar I; Dias-Barbosa C; Kirby JS Dermatology; 2024; 240(1):65-76. PubMed ID: 37820596 [TBL] [Abstract][Full Text] [Related]
18. Randomized Controlled Trials for the Treatment of Hidradenitis Suppurativa. van Rappard DC; Mekkes JR; Tzellos T Dermatol Clin; 2016 Jan; 34(1):69-80. PubMed ID: 26617360 [TBL] [Abstract][Full Text] [Related]